Vascular Graft Infections: An Overview of Novel Treatments Using Nanoparticles and Nanofibers
Vascular disease in elderly patients is a growing health concern, with an estimated prevalence of 15–20% in patients above 70 years old. Current treatment for vascular diseases requires the use of a vascular graft (VG) to revascularize lower or upper extremities, create dialysis access, treat aortic aneurysms, and repair dissection. However, postoperative infection is a major complication associated with the use of these VG, often necessitating several operations to achieve complete or partial graft excision, vascular coverage, and extra-anatomical revascularization. There is also a high risk of morbidity, mortality, and limb loss. Therefore, it is important to develop a method to prevent or reduce the incidence of these infections. Numerous studies have investigated the efficacy of antibiotic- and antiseptic-impregnated grafts. In comparison to these traditional methods of creating antimicrobial grafts, nanotechnology enables researchers to design more efficient VG. Nanofibers and nanoparticles have a greater surface area compared to bulk materials, allowing for more efficient encapsulation of antibiotics and better control over their temporo-spatial release. The disruptive potential of nanofibers and nanoparticles is exceptional, and they could pave the way for a new generation of prosthetic VG. This review aims to discuss how nanotechnology is shaping the future of cardiovascular-related infection management..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:10 |
|---|---|
| Enthalten in: |
Fibers - 10(2022), 2, p 12 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Emma He [VerfasserIn] |
|---|
| Links: |
doi.org [kostenfrei] |
|---|
| Themen: |
Biology (General) |
|---|
| doi: |
10.3390/fib10020012 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
DOAJ030425913 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ030425913 | ||
| 003 | DE-627 | ||
| 005 | 20240414185859.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3390/fib10020012 |2 doi | |
| 035 | |a (DE-627)DOAJ030425913 | ||
| 035 | |a (DE-599)DOAJ779806ecd9b34dcaae24c65501066a2a | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 050 | 0 | |a TP200-248 | |
| 050 | 0 | |a TP890-933 | |
| 050 | 0 | |a QH301-705.5 | |
| 050 | 0 | |a QC1-999 | |
| 100 | 0 | |a Emma He |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Vascular Graft Infections: An Overview of Novel Treatments Using Nanoparticles and Nanofibers |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Vascular disease in elderly patients is a growing health concern, with an estimated prevalence of 15–20% in patients above 70 years old. Current treatment for vascular diseases requires the use of a vascular graft (VG) to revascularize lower or upper extremities, create dialysis access, treat aortic aneurysms, and repair dissection. However, postoperative infection is a major complication associated with the use of these VG, often necessitating several operations to achieve complete or partial graft excision, vascular coverage, and extra-anatomical revascularization. There is also a high risk of morbidity, mortality, and limb loss. Therefore, it is important to develop a method to prevent or reduce the incidence of these infections. Numerous studies have investigated the efficacy of antibiotic- and antiseptic-impregnated grafts. In comparison to these traditional methods of creating antimicrobial grafts, nanotechnology enables researchers to design more efficient VG. Nanofibers and nanoparticles have a greater surface area compared to bulk materials, allowing for more efficient encapsulation of antibiotics and better control over their temporo-spatial release. The disruptive potential of nanofibers and nanoparticles is exceptional, and they could pave the way for a new generation of prosthetic VG. This review aims to discuss how nanotechnology is shaping the future of cardiovascular-related infection management. | ||
| 650 | 4 | |a vascular grafts | |
| 650 | 4 | |a infections | |
| 650 | 4 | |a nanofibers | |
| 650 | 4 | |a electrospinning | |
| 650 | 4 | |a nanoparticles | |
| 653 | 0 | |a Chemicals: Manufacture, use, etc. | |
| 653 | 0 | |a Textile bleaching, dyeing, printing, etc. | |
| 653 | 0 | |a Biology (General) | |
| 653 | 0 | |a Physics | |
| 700 | 0 | |a Stefano Serpelloni |e verfasserin |4 aut | |
| 700 | 0 | |a Phillip Alvear |e verfasserin |4 aut | |
| 700 | 0 | |a Maham Rahimi |e verfasserin |4 aut | |
| 700 | 0 | |a Francesca Taraballi |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t Fibers |d MDPI AG, 2013 |g 10(2022), 2, p 12 |w (DE-627)DOAJ000030759 |x 20796439 |7 nnns |
| 773 | 1 | 8 | |g volume:10 |g year:2022 |g number:2, p 12 |
| 856 | 4 | 0 | |u https://doi.org/10.3390/fib10020012 |z kostenfrei |
| 856 | 4 | 0 | |u https://doaj.org/article/779806ecd9b34dcaae24c65501066a2a |z kostenfrei |
| 856 | 4 | 0 | |u https://www.mdpi.com/2079-6439/10/2/12 |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/2079-6439 |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 951 | |a AR | ||
| 952 | |d 10 |j 2022 |e 2, p 12 | ||